Rogne Bioscience Inc.
Testing an anti-inflammatory human peptide for topical use against psoriasis
This article was originally published in Start Up
Executive Summary
The cost/efficacy argument over high-priced biological treatments for psoriasis has created a market opportunity that Rogne Bioscience Inc. intends to exploit. Instead of developing another injectable protein like so many others, the start-up is developing a topical formulation of a human peptide that it describes as “the off-switch for inflammation.”